Anakinra
- Generic Name
- Anakinra
- Brand Names
- Kineret
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 143090-92-0
- Unique Ingredient Identifier
- 9013DUQ28K
- Background
Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the managemen...
- Indication
Anakinra is an interleukin-1 receptor antagonist indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis (RA), in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs). Anakinra can be used alone or in combin...
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19), Cryopyrin-associated Periodic Syndromes (CAPS), Deficiency of the interleukin-1 receptor antagonist, Idiopathic Recurrent Pericarditis, Moderately to Severely Active Rheumatoid Arthritis, Neonatal-Onset Multisystem Inflammatory Disease (NOMID), Systemic Juvenile Idiopathic Arthritis (SJIA)
- Associated Therapies
- -
Anakinra in Dengue With Hyperinflammation ( AnaDen )
- First Posted Date
- 2022-11-10
- Last Posted Date
- 2024-11-22
- Target Recruit Count
- 160
- Registration Number
- NCT05611710
- Locations
- 🇻🇳
Hospital for Tropical Diseases, Ho Chi Minh, Vietnam
The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Herlev and Gentofte Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05498467
Anakinra for Preterm Infants Pilot
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- Monash Medical Centre
- Target Recruit Count
- 24
- Registration Number
- NCT05280340
- Locations
- 🇦🇺
Monash Health, Clayton, Victoria, Australia
🇳🇿Starship Children's Hospital, Te Whatu Ora - Health New Zealand, Grafton, Auckland, New Zealand
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
- Conditions
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Nationwide Children's Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT05267821
- Locations
- 🇺🇸
University of California, Davis, Sacremento, California, United States
🇺🇸Riley Children's Hospital, Indianapolis, Indiana, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 84
- Registration Number
- NCT05177822
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸Virginia Commonwealth University, Richmond, Virginia, United States
Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes
- Conditions
- Interventions
- First Posted Date
- 2021-12-30
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 26
- Registration Number
- NCT05174507
- Locations
- 🇨🇭
Department of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Basel, Switzerland
Discovery and Analytical Validation of Inflammatory Bio-signatures of the Human Pain Experience
- Conditions
- Interventions
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Alan Prossin
- Target Recruit Count
- 70
- Registration Number
- NCT05074485
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
Dupilumab_Metastatic NSCLC
- Conditions
- Interventions
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Thomas Marron
- Target Recruit Count
- 21
- Registration Number
- NCT05013450
- Locations
- 🇺🇸
Tisch Cancer Institute, Mount Sinai Hospital, New York, New York, United States
🇺🇸The Blavatnik Family-Chelsea Medical Center at Mount Sinai, New York, New York, United States
Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 24
- Registration Number
- NCT04926467
- Locations
- 🇺🇸
Baylor University Medical Center, Charles A Sammons Cancer Center, Dallas, Texas, United States
MIS-C Comparative Effectiveness Study
- Conditions
- Interventions
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 73
- Registration Number
- NCT04898231
- Locations
- 🇺🇸
Rady Children's Hospital, San Diego, California, United States
🇺🇸Children's Hospital Michigan, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.